Muckle-Wells syndrome


Also found in: Acronyms, Wikipedia.

Muck·le-Wells syn·drome

(muk'ĕl welz), [MIM*191900]
a syndrome characterized by amyloidosis, notably involving the kidneys, progressive sensorineural hearing loss, and periods of febrile urticaria associated with pain in joints and muscles of the extremities; autosomal dominant inheritance.

Muckle,

Thomas James, 20th century Canadian pediatrician.
Muckle-Wells syndrome - a syndrome characterized by familial amyloidosis.

Wells,

Michael Vernon, 20th century English physician.
Muckle-Wells syndrome - see under Muckle
References in periodicals archive ?
Muckle-Wells syndrome without mutation in exon 3 of the NLRP3 gene, identified by evidence of excessive monocyte production of functional interleukin 1[sz] and rapid response to anakinra.
Three related conditions make up the broader disease known as CAPS: Familial Cold Auto-inflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal-Onset Multisystem Inflammatory Disease (NOMID).
Muckle-Wells syndrome is more severe; patients also may haw sensorineural hearing loss, conjunctivitis, retinitis, arthritis, periodic fevers, abdominal pain, and amyloidosis.
Nasdaq: REGN) today announced ARCALYST[TM] (rilonacept) Injection for Subcutaneous Use is now available for prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
Food and Drug Administration (FDA) for ARCALYST[TM] (rilonacept) Injection for Subcutaneous Use, an interleukin-1 blocker, for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.
Cryopyrin-Associated Periodic Syndromes (CAPS) is a spectrum of rare inherited inflammatory conditions, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
Currently, there are no medicines approved for patients suffering from CAPS, a spectrum of rare inherited inflammatory conditions, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
The trial was designed to provide two separate demonstrations of efficacy for the IL-1 Trap, a long-acting IL-1 inhibitor, in adult patients suffering from Familial Cold Autoinflammatory Syndrome (FCAS) or Muckle-Wells Syndrome (MWS).
CIAS1-related Autoinflammatory Periodic Syndromes (CAPS) is a spectrum of rare inherited inflammatory conditions, including Familial Cold Autoinflammatory Syndrome (FCAS), Muckle-Wells Syndrome (MWS), and Neonatal Onset Multisystem Inflammatory Disease (NOMID).